FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1469R1C1	10/624,153
Applicant: Yvonne Chen et al.	
Filing Date: 21 Jul 2003	Group: 1641

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
LAB	* 1	5,821,337	13.10.98	Carter et al.			
	* 2	6,010,861	04.01.00	Blume, A.			
	* 3	6,037,454	14.03.00	Jardieu et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
LAB	* 4	2,125,240	07.12.95	CANADA				
	* 5	91-40386	03.06.97	JAPAN (ABSTRACT ONLY)				
	* 6	WO 97/31024	28.08.97	PCT				
	* 7	WO 98/23746	04.06.98	PCT				
	* 8	WO 98/23761	04.06.98	PCT				
	* 9	WO 98/45331	15.10.98	PCT				
	*10	WO 98/45332	15.10.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials		
LAB	*11	Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution" Science 233:747-753 (Aug 1986)
	*12	Balint and Larrick, "Antibody engineering by parsimonious mutagenesis" Gene 137(1):109-118 (Dec 27, 1993)
	*13	Barbas III et al., "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity." Proc. Natl. Acad. Sci. USA 91(9):3809-3813 (Apr 26, 1994)
	*14	Brunger et al., "Crystallographic R factor refinement by molecular dynamics" Science 235:458-460 (Jan 23, 1987)
	*15	Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" Trends In Biotechnology 10(3):80-84 (Mar 1992)
	*16	Fenney and Thuerauf, "Sequence and fine specificity analysis of primary 511 anti-phosphorylcholine antibodies" Journal of Immunology 143(12):4061-4068 (Dec 15, 1989)
	*17	Gazzano-Santoro et al., "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody." Journal of Immunological Methods. 202:163-171 (1997)
	*18	Groves et al., "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion" Hybridoma 6(1):71-76 (Feb 1987)
	*19	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" J. Mol. Biol. 226:889-896 (1992)
	*20	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." Nature. 321:522-525 (May 29, 1986)
	*21	Kabat. Sequences of Proteins of Immunological Interest, US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)
	*22	LeBlanc et al., "Recognition properties of a sequence-specific DNA binding antibody" Biochemistry 37(17):6015-6022 (Apr 28, 1998)

Examiner: Lynn Bazil

Date Considered: 4/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1469R1C1	Serial No. 10/624,153
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Yvonne Chen et al.	
		Filing Date 21 Jul 2003	Group 1641

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

LAB	*23	Lee et al., "Strong inhibition of fibrinogen binding to platelet receptor $\alpha_{IIb}\beta_3$ by RGD sequences installed into a presentation scaffold" Protein Engineering 6(7):745-754 (Sep 1993)
	*24	McLane et al., "Transplantation of a 17-amino acid α-helical DNA-binding domain into an antibody molecule confers sequence-dependent DNA recognition" Proc. Natl. Acad. Sci. USA 92(11):5214-5218 (May 23, 1995)
	*25	Muller et al., "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface" Structure 6(9):1153-1167 (Sep 15, 1998)
	*26	Ohlin and Borrebaeck, "Insertions and deletions in hypervariable loops of antibody heavy chains contribute to molecular diversity" Molecular Immunology 35(4):233-238 (Mar 1998)
	*27	Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" Proc. Natl. Acad. Sci. USA 85:3080-3084 (May 1988)
	*28	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" Cancer Research 57(20):4593-4599 (Oct 15, 1997)
	*29	Rader and Barbas III, "Phage display of combinatorial antibody libraries" Current Opinion in Biotechnology 8(4):503-508 (Aug 1997)
	*30	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity" Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982)
	*31	Schier et al., "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site" Journal of Molecular Biology 263(4):551-567 (Nov 8, 1996)
	*32	Sheets et al., "Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens" Proc. Natl. Acad. Sci. USA 95(11):6157-6162 (May 26, 1998)
	*33	Simon and Rajewsky, "A functional antibody mutant with an insertion in the framework region 3 loop of the V_H domain: implications for antibody engineering" Protein Engineering 5(3):229-234 (Apr 1992)
	*34	Thompson et al., "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity" Journal of Molecular Biology 256(1):77-88 (Feb 16, 1996)
	*35	Wilson et al., "Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes" Journal of Experimental Medicine 187(1):59-70 (Jan 5, 1998)
	*36	Wu et al., "Stepwise in vitro affinity maturation of Vitaxin, an $\alpha_v\beta_3$-specific humanized mAb" Proc. Natl. Acad. Sci. USA 95(11):6037-6042 (May 26, 1998)
	*37	Yang et al., "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range" Journal of Molecular Biology 254(3):392-403 (Dec 1, 1995)
	*38	Zhao et al., "A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold" Nature Structural Biology 2(12):1131-1137 (Dec 1995)

Examiner	Date Considered
Lynn Bertold	4/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.